

Astrid Maria Thomas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9025949/publications.pdf>

Version: 2024-02-01

68
papers

2,853
citations

136950

32
h-index

182427

51
g-index

72
all docs

72
docs citations

72
times ranked

3389
citing authors

#	ARTICLE	IF	CITATIONS
1	EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. <i>Brain</i> , 2008, 131, 690-705.	7.6	292
2	Pathological gambling in Parkinson disease is reduced by amantadine. <i>Annals of Neurology</i> , 2010, 68, 400-404.	5.3	201
3	Reversible parkinsonism induced by prolonged treatment with valproate. <i>Journal of Neurology</i> , 1998, 245, 794-796.	3.6	109
4	Botulinum toxin treatment of lateral axial dystonia in parkinsonism. <i>Movement Disorders</i> , 2007, 22, 2097-2103.	3.9	107
5	Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2015, 36, 434-445.	3.1	99
6	Default network is not hypoactive in dementia with fluctuating cognition: an Alzheimer disease/dementia with Lewy bodies comparison. <i>Neurobiology of Aging</i> , 2013, 34, 1148-1158.	3.1	92
7	Acute akinesia in Parkinson disease. <i>Neurology</i> , 2005, 64, 1162-1169.	1.1	91
8	The Characterization of Regulatory T-Cell Profiles in Alzheimer's Disease and Multiple Sclerosis. <i>Scientific Reports</i> , 2019, 9, 8788.	3.3	90
9	Cohort study on somatoform disorders in Parkinson disease and dementia with Lewy bodies. <i>Neurology</i> , 2010, 74, 1598-1606.	1.1	88
10	Donepezil, Rivastigmine, and Vitamin E in Alzheimer Disease: A Combined P300 Event-related Potentials/Neuropsychologic Evaluation over 6 Months. <i>Clinical Neuropharmacology</i> , 2001, 24, 31-42.	0.7	77
11	Thalamic Involvement in Fluctuating Cognition in Dementia with Lewy Bodies: Magnetic Resonance Evidences. <i>Cerebral Cortex</i> , 2015, 25, 3682-3689.	2.9	73
12	Pisa syndrome in Parkinson disease. <i>Neurology</i> , 2015, 85, 1769-1779.	1.1	72
13	An expert opinion on safinamide in Parkinson's disease. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1115-1125.	4.1	71
14	The Effects of a Cholinesterase Inhibitor Are Prominent in Patients With Fluctuating Cognition: A Part 3 Study of the Main Mechanism of Cholinesterase Inhibitors in Dementia. <i>Clinical Neuropharmacology</i> , 2003, 26, 239-251.	0.7	70
15	Default mode network links to visual hallucinations: A comparison between Parkinson's disease and multiple system atrophy. <i>Movement Disorders</i> , 2015, 30, 1237-1247.	3.9	70
16	Structural Alteration of the Dorsal Visual Network in DLB Patients with Visual Hallucinations: A Cortical Thickness MRI Study. <i>PLoS ONE</i> , 2014, 9, e86624.	2.5	53
17	Atrophy of hippocampal subfields and adjacent extrahippocampal structures in dementia with Lewy bodies and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2016, 40, 103-109.	3.1	52
18	Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions. <i>Frontiers in Neurology</i> , 2021, 12, 644317.	2.4	51

#	ARTICLE	IF	CITATIONS
19	Donepezil Versus Vitamin E in Alzheimer's Disease Part 2: Mild Versus Moderateâ€“Severe Alzheimer's Disease. <i>Clinical Neuropharmacology</i> , 2002, 25, 207-215.	0.7	50
20	Two novel POLG1 mutations in a patient with progressive external ophthalmoplegia, levodopa-responsive pseudo-orthostatic tremor and parkinsonism. <i>Neuromuscular Disorders</i> , 2008, 18, 460-464.	0.6	49
21	Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment. <i>Parkinsonism and Related Disorders</i> , 2009, 15, S233-S236.	2.2	46
22	Effects of dexamipexole on brain mitochondrial conductances and cellular bioenergetic efficiency. <i>Brain Research</i> , 2012, 1446, 1-11.	2.2	46
23	Autoscopic phenomena: case report and review of literature. <i>Behavioral and Brain Functions</i> , 2011, 7, 2.	3.3	45
24	Early-onset parkinsonism caused by alpha-synuclein gene triplication: Clinical and genetic findings in a novel family. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 981-986.	2.2	45
25	Dopa-responsive pseudo-orthostatic tremor in parkinsonism. <i>Movement Disorders</i> , 2007, 22, 1652-1656.	3.9	44
26	Updates on Somatoform Disorders (SFMD) in Parkinson's Disease and Dementia with Lewy Bodies and discussion of phenomenology. <i>Journal of the Neurological Sciences</i> , 2011, 310, 166-171.	0.6	43
27	Acetyl-<sc>L</sc>-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond. <i>Expert Review of Neurotherapeutics</i> , 2013, 13, 925-936.	2.8	43
28	A Stage-Based Approach to Therapy in Parkinsonâ€™s Disease. <i>Biomolecules</i> , 2019, 9, 388.	4.0	41
29	Structural Connectivity is Differently Altered in Dementia with Lewy Body and Alzheimerâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 208.	3.4	38
30	Relevance of subcortical visual pathways disruption to visual symptoms in dementia with Lewy bodies. <i>Cortex</i> , 2014, 59, 12-21.	2.4	37
31	Fluctuating cognition and different cognitive and behavioural profiles in Parkinsonâ€™s disease with dementia: comparison of dementia with Lewy bodies and Alzheimerâ€™s disease. <i>Journal of Neurology</i> , 2010, 257, 1004-1011.	3.6	36
32	New approaches to understanding hallucinations in Parkinsonâ€™s disease: phenomenology and possible origins. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1731-1750.	2.8	35
33	Akinetic crisis, acute akinesia, neuroleptic malignantâ€“like syndrome, Parkinsonismâ€“hyperpyrexia syndrome, and malignant syndrome are the same entity and are often independent of treatment withdrawal. <i>Movement Disorders</i> , 2005, 20, 1671-1671.	3.9	33
34	HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease. <i>Movement Disorders</i> , 2003, 18, 337-340.	3.9	30
35	Paradoxical kinesia in parkinsonian patients surviving earthquake. <i>Movement Disorders</i> , 2010, 25, 1302-1304.	3.9	29
36	End-of-dose deterioration in non ergolinic dopamine agonist monotherapy of Parkinsonâ€™s disease. <i>Journal of Neurology</i> , 2006, 253, 1633-1639.	3.6	26

#	ARTICLE	IF	CITATIONS
37	Delayed blink reflex in dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1137-1139.	1.9	26
38	Cohort study of prevalence and phenomenology of tremor in dementia with Lewy bodies. Journal of Neurology, 2013, 260, 1731-1742.	3.6	23
39	Somatization in Parkinson's Disease: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 78, 18-26.	4.8	23
40	GIGYF2 mutations are not a frequent cause of familial Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 703-705.	2.2	22
41	Amyloid-specific T-cells differentiate Alzheimer's disease from Lewy body dementia. Neurobiology of Aging, 2012, 33, 2599-2611.	3.1	22
42	Source model and scalp topography of pattern reversal visual evoked potentials to altitudinal stimuli suggest that infoldings of calcarine fissure are not part of VEP generators. Brain Topography, 1995, 7, 217-231.	1.8	20
43	Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology, 2003, 61, 1452-1452.	1.1	20
44	Amantadine and cognitive flexibility: decision making in Parkinson's patients with severe pathological gambling and other impulse control disorders. Neuropsychiatric Disease and Treatment, 2014, 10, 1093.	2.2	20
45	Visual Evoked Potentials Generator Model Derived from Different Spatial Frequency Stimuli of Visual Field Regions and Magnetic Resonance Imaging Coordinates of V1, V2, V3 Areas in Man. International Journal of Neuroscience, 1995, 83, 213-239.	1.6	18
46	Morphological and Metabolic Changes in the Nigro-Striatal Pathway of Synthetic Proteasome Inhibitor (PSI)-Treated Rats: A MRI and MRS Study. PLoS ONE, 2013, 8, e56501.	2.5	16
47	Modafinil and armodafinil improve attention and global mental status in Lewy bodies disorders: preliminary evidence. International Journal of Geriatric Psychiatry, 2013, 28, 1095-1097.	2.7	14
48	Nonepileptic seizures under levetiracetam therapy: a case report of forced normalization process. Neuropsychiatric Disease and Treatment, 2014, 10, 959.	2.2	14
49	One Further Case of Pancytopenia Induced by Olanzapine in a Parkinson's Disease Patient. European Neurology, 2001, 45, 56-57.	1.4	13
50	Psychosis in parkinsonism: an unorthodox approach. Neuropsychiatric Disease and Treatment, 2017, Volume 13, 1313-1330.	2.2	13
51	Task-specific lower lip dystonia due to mantra recitation. Movement Disorders, 2007, 22, 439-440.	3.9	12
52	Acetazolamide-responsive periodic ataxia induced by amiodarone. Movement Disorders, 1999, 14, 379-381.	3.9	10
53	Responsiveness of dysphagia to acute L-Dopa challenge in progressive supranuclear palsy. Journal of Neurology, 2014, 261, 441-442.	3.6	10
54	Functional neurological disorder and somatic symptom disorder in Parkinson's disease. Journal of the Neurological Sciences, 2022, 433, 120017.	0.6	10

#	ARTICLE	IF	CITATIONS
55	Delayed Blink Reflex in Dementia With Lewy Bodies Is Sensitive to Cholinergic Modulation. <i>Clinical Neuropharmacology</i> , 2008, 31, 231-237.	0.7	9
56	Cortical Activation During Levitation and Tentacular Movements of Corticobasal Syndrome. <i>Medicine (United States)</i> , 2015, 94, e1977.	1.0	9
57	Visual Hallucinations as Incidental Negative Effects of Virtual Reality on Parkinson's Disease Patients: A Link with Neurodegeneration?. <i>Parkinson's Disease</i> , 2015, 2015, 1-6.	1.1	9
58	Preexisting Bipolar Disorder Influences the Subsequent Phenotype of Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 2840-2852.	3.9	8
59	Optic Neuritis with Residual Tunnel Vision in Perchloroethylene Toxicity. <i>Journal of Toxicology: Clinical Toxicology</i> , 1998, 36, 603-607.	1.5	6
60	Eyelid retraction in dementia with Lewy bodies and Parkinson's disease. <i>Journal of Neurology</i> , 2011, 258, 1542-1544.	3.6	5
61	Electrophysiological indices of interference resolution covary with individual fluid intelligence: investigating reactive control processes in a 3-back working memory task. <i>NeuroImage</i> , 2014, 93, 146-153.	4.2	4
62	A Critical Review of Alien Limb-Related Phenomena and Implications for Functional Magnetic Resonance Imaging Studies. <i>Frontiers in Neurology</i> , 2021, 12, 661130.	2.4	4
63	Somatoform Disorders in Parkinson's Disease and Dementia with Lewy Bodies Evidence Underlying Psychotic Traits. <i>Advances in Biological Psychiatry</i> , 2012, , 125-132.	0.2	3
64	Optic Neuritis with Residual Tunnel Vision in Perchloroethylene Toxicity. <i>European Neurology</i> , 1999, 41, 51-53.	1.4	2
65	Amantadine and anticholinergic drugs in the management of Parkinson's disease. , 0, , 13-22.		2
66	Sporadic acetazolamide-responsive episodic ataxia. <i>Movement Disorders</i> , 1999, 14, 1055-1056.	3.9	1
67	Critical Illness Neuromyopathy Complicating Akinetic Crisis in Parkinsonism. <i>Medicine (United States)</i> , 2015, 94, e1118.	1.0	1
68	Reply: Is cognition key in paradoxical kinesia?. <i>Movement Disorders</i> , 2011, 26, 365-365.	3.9	0